Dutch-US MedTech Xeltis Raises €20.5 Million to Advance Artificial Vessels and Valves Replaced by Patients’ Own Tissue

Dutch-US MedTech Xeltis raises €20.5 million to advance artificial vessels and valves replaced by patients’ own tissue

Xeltis, a commercial-stage MedTech company based in the Netherlands and the USA, developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue, has raised an additional €20.5 million in new funding. This funding was secured from new and existing shareholders. The round was led by new investor Horizon 3 Healthcare, with participation from the European Innovation Council, Invest-NL, VI Partners, EQT Li…

Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch

New investor Horizon 3 Healthcare led the round, which was supported by the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders Builds on the €50m secured in 2025 and supports Xeltis’ next phase of clinical, regulatory and commercial execution Additional €20.5m provides the runway to finalize the ongoing US […] The post Xeltis raises an additional €20.5m of funding to advance aXess™ towar…